207 related articles for article (PubMed ID: 16082381)
1. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D
Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours.
Habib NA; Hodgson HJ; Lemoine N; Pignatelli M
Hum Gene Ther; 1999 Aug; 10(12):2019-34. PubMed ID: 10466636
[TBL] [Abstract][Full Text] [Related]
4. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
[TBL] [Abstract][Full Text] [Related]
5. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
Anderson SC; Johnson DE; Harris MP; Engler H; Hancock W; Huang WM; Wills KN; Gregory RJ; Sutjipto S; Wen SF; Lofgren S; Shepard HM; Maneval DC
Clin Cancer Res; 1998 Jul; 4(7):1649-59. PubMed ID: 9676839
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal carcinoma.
Maron DJ; Tada H; Moscioni AD; Tazelaar J; Fraker DL; Wilson JM; Spitz FR
Mol Ther; 2001 Jul; 4(1):29-35. PubMed ID: 11472103
[TBL] [Abstract][Full Text] [Related]
8. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
[TBL] [Abstract][Full Text] [Related]
9. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
Tian G; Liu J; Zhou JS; Chen W
Anticancer Drugs; 2009 Jun; 20(5):389-95. PubMed ID: 19287305
[TBL] [Abstract][Full Text] [Related]
10. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
Wen SF; Mahavni V; Quijano E; Shinoda J; Grace M; Musco-Hobkinson ML; Yang TY; Chen Y; Runnenbaum I; Horowitz J; Maneval D; Hutchins B; Buller R
Cancer Gene Ther; 2003 Mar; 10(3):224-38. PubMed ID: 12637944
[TBL] [Abstract][Full Text] [Related]
11. Signaling antibodies complexed with adenovirus circumvent CAR and integrin interactions and improve gene delivery.
Li E; Brown SL; Von Seggern DJ; Brown GB; Nemerow GR
Gene Ther; 2000 Sep; 7(18):1593-9. PubMed ID: 11021598
[TBL] [Abstract][Full Text] [Related]
12. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
14. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
16. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
[TBL] [Abstract][Full Text] [Related]
17. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors.
Okimoto T; Yahata H; Itou H; Shinozaki K; Tanji H; Sakaguchi T; Asahara T
J Exp Clin Cancer Res; 2003 Sep; 22(3):399-406. PubMed ID: 14582698
[TBL] [Abstract][Full Text] [Related]
18. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
19. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
